HDL cholesterol levels not linked to risk of developing movement disorders, suggests research
HDL cholesterol levels not linked to risk of developing movement disorders, suggests research published in the Innovations in Clinical Neuroscience.
Well-known adverse events of antipsychotics are movement disorders, or extrapyramidal symptoms, such as drug-induced parkinsonism and tardive dyskinesia. With new evidence suggesting a link between low high-density lipoprotein cholesterol (HDL-C) and risk of Parkinson’s disease, this study sought to investigate if that link also translated to patients taking antipsychotics with low HDL-C and an increased risk for developing a movement disorder.
Adult patients (n=89) at an inpatient state psychiatric facility taking at least one antipsychotic with at least one HDL-C level were assessed for signs of a movement disorder through their history and physical, progress notes, and Abnormal Involuntary Movement Scale (AIMS) score. Results: There was no statistical significance when comparing a patient’s movement disorder, AIMS scores, and HDL-C levels to suggest that the HDL-C level influenced a patient’s movement disorder.
This study did not show a correlation between HDL-C levels and a patient’s risk of developing a movement disorder while taking an antipsychotic.
Reference:
O'Donnell C, Demler TL, Trigoboff E, Lee C. The Impact of High-density Lipoprotein Cholesterol (HDL-C) Levels and Risk of Movement Disorders in Patients Taking Antipsychotics. Innov Clin Neurosci. 2024 Jun 1;21(4-6):27-30. PMID: 38938537; PMCID: PMC11208005.
